# Phase IIb Study of AST-3424 in Patients With AKR1C3-high Expressing Advanced Hepatocellular Carcinoma

Source: https://onco.cc/trials/nct07310173/  
OnCo record `nct07310173` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 2 trial of Regorafenib in hepatocellular carcinoma, run by Zhejiang Hisun Pharmaceutical Co. Ltd., now recruiting.

## Summary

Phase IIb Study of AST-3424 in Patients With AKR1C3-high Expressing Advanced Hepatocellular Carcinoma is a phase 2 interventional study registered as NCT07310173 by Zhejiang Hisun Pharmaceutical Co. Ltd., with 75 participants planned, started 2026-01-01 and due to reach its primary completion in 2027-10-01. Interventions recorded: AST-3424, Regorafenib Tablets. Conditions listed: HCC - Hepatocellular Carcinoma. No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-16
- Tags: ctgov-ingest
- Registry id: NCT07310173
- Phase: 2
- Setting: Phase IIb, Randomized, Active-Controlled, Parallel-Group, Multicenter Clinical Study to Evaluate the Efficacy and Safety of AST-3424 in Patients With AKR1C3-High Expressing Advanced Hepatocellular Carcinoma Who Progressed After Systemic Therapy With Immune Checkpoint Inhibitors
- Sponsor: Zhejiang Hisun Pharmaceutical Co. Ltd.
- Enrolled: 75

## Sources

- ClinicalTrials.gov NCT07310173: https://clinicaltrials.gov/study/NCT07310173

## Connected records

- cancers: [Hepatocellular carcinoma](https://onco.cc/cancers/hcc/)
- drugs: [Regorafenib](https://onco.cc/drugs/regorafenib/)
- companies: [Zhejiang Hisun Pharmaceutical](https://onco.cc/companies/zhejiang-hisun/)

---
JSON: https://onco.cc/api/v1/entities/nct07310173.json